The role of aromatase inhibitors in the treatment of infertility in obese Male


Status: Recruiting
Keywords: Infertility , Male Infertility , Obese Men and Infertility , Obesity
IRB Number: 00016246
Specialty: Reproductive Endocrinology and Infertility
Sub Specialties:

Brief Summary

This project aim to study the role of aromatase inhibitors, in particular anastrozole, in the treatment of infertility in obese male. Obese male with sperm count between 5-15 million/ml will be randomized to receive anastrozole (1mg/day) or placebo. After 4 month of treatment, the final outcome will be improvement in sperm count.

Principal Investigator: Ahmad Hammoud
Department: Obstetrics And Gynecology (Dept)
Co Investigator: Douglas Carrell
Co Investigator: Matthew Peterson

Contact Information

Name:Denise Lamb
Phone: 8015871180

Inclusion Criteria

1. Male partner of a couple presenting for infertility work up after one year of unprotected intercourse.

2. Moderate oligozoospermia (defined as sperm count ≤ 15 × 106/mL and ≥ than 5 × 106/mL) on at least two separate occasions spanning a minimum of two weeks.

3. Obese men BMI ≥ 30

4. FSH and LH levels < 10 mIU/mL

Exclusion Criteria

1. Severe Oligozoospermia: Sperm count < than 5 × 106/mL, including azoospermia.2. Age less than 18 or greater than 65 years3. Pyospermia or leukospermia: defined by white blood cells ≥1 million leukocytes per milliliter of semen. 4. Cryptorchidism5. Vasectomy reversal 6.Regular use of tobacco products7. BMI < 30 8. Use of anabolic steroids or testosterone replacement